Physician profile
Ammar Kheder
NPI 1770925976
$12,016.49
in general payments reported to CMS, 2019-2025
9 companies · $2,613 in 2025
The $2,613 reported for 2025 was more than what 80% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.31 · 2021: $25.00 · 2022: $4,897 · 2023: $4,243 · 2024: $142 · 2025: $2,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,500 · Travel and Lodging: $2,470 · Food and Beverage: $2,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,500.00 |
| Travel and Lodging | $2,469.65 |
| Food and Beverage | $2,028.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dixi Medical USA Corp | $9,165.55 | 2021-2023 | |
| Aucta Pharmaceuticals, INC. | $2,500.00 | 2025 | Motpoly Xr |
| Eisai INC. | $96.31 | 2019 | |
| Neurelis, INC. | $89.60 | 2024 | Valtoco |
| Sk Life Science, INC. | $64.25 | 2025 | Xcopri |
| Catalyst Pharmaceuticals, INC. | $52.12 | 2024 | |
| Ucb, INC. | $25.97 | 2025 | Fintepla |
| Neurocrine Biosciences, INC. | $22.69 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Kheder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.